drugset / Trial / NCT00558727
Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, nonrandomized, open-label, dose-escalation study of 3-hour IV infusions of RH-1 administered to patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL). Treatment will continue until a patient meets criteria for discontinuation.
Timeline
- Start
- 2007-11
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RH-1 | Unknown | 1.5 mg/m2 | Intravenous |
| Subject | RH-1 | Unknown | 12 mg/m2 | Intravenous |